NMC
NEA Management Company Portfolio holdings
AUM
$1.33B
This Quarter Return
+19.36%
1 Year Return
+85.82%
3 Year Return
+531.37%
5 Year Return
+304.32%
10 Year Return
+4,927.96%
AUM
$1.31B
AUM Growth
+$1.31B
(-9.4%)
Cap. Flow
-$2.9B
Cap. Flow
% of AUM
-221.62%
Top 10 Holdings %
Top 10 Hldgs %
64.88%
Holding
54
New
1
Increased
4
Reduced
9
Closed
10
Top Buys
| 1 |
Phathom Pharmaceuticals
PHAT
|
$18.3M |
| 2 |
X4 Pharmaceuticals
XFOR
|
$6.31M |
| 3 |
Black Diamond Therapeutics
BDTX
|
$5.05M |
| 4 |
RGLS
Regulus Therapeutics
RGLS
|
$736K |
| 5 |
DM
Desktop Metal, Inc.
DM
|
$15.3K |
Top Sells
| 1 |
NeueHealth
NEUE
|
$2.63B |
| 2 |
IonQ
IONQ
|
$89.9M |
| 3 |
Cloudflare
NET
|
$77M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
$51.7M |
| 5 |
Arcellx
ACLX
|
$31.6M |
Sector Composition
| 1 | Healthcare | 76.63% |
| 2 | Consumer Staples | 12.79% |
| 3 | Industrials | 7.44% |
| 4 | Technology | 2.55% |
| 5 | Communication Services | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Coursera
COUR
$1.88B
| $168M | 12.79% | 12,867,769 | – | – |
|
|
2
Arcellx
ACLX
$3.85B
| $118M | 9.04% | 3,745,262 -1,000,000 | -21% | -$31.6M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $118M | 9.01% | 5,108,563 -476,190 | -9% | -$11M |
|
4
CRISPR Therapeutics
CRSP
$4.71B
| $89.1M | 6.8% | 1,587,854 | – | – |
|
5
Savara
SVRA
$567M
| $77.1M | 5.89% | 24,137,931 | – | – |
|
6
Geron
GERN
$893M
| $68.5M | 5.23% | 21,347,838 | – | – |
|
|
7
Mirum Pharmaceuticals
MIRM
$3.71B
| $56.6M | 4.32% | 2,186,243 -2,000,000 | -48% | -$51.7M |
|
|
BGRY
8
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
| $53.8M | 4.11% | 38,183,023 | – | – |
|
9
Monte Rosa Therapeutics
GLUE
$296M
| $52.7M | 4.02% | 7,692,298 | – | – |
|
10
Rhythm Pharmaceuticals
RYTM
$6.85B
| $48M | 3.66% | 2,909,956 | – | – |
|
11
Aurinia Pharmaceuticals
AUPH
$1.58B
| $38.4M | 2.93% | 3,969,834 | – | – |
|
12
CVRx
CVRX
$205M
| $36.6M | 2.79% | 2,370,542 | – | – |
|
|
13
NeueHealth
NEUE
$59.2M
| $33.3M | 2.54% | 2,726,917 -215,426,706 | -99% | -$2.63B |
|
|
14
X4 Pharmaceuticals
XFOR
$84.2M
| $29.1M | 2.22% | 14,986,793 +3,250,000 | +28% | +$6.31M |
|
|
OKUR
15
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $28.3M | 2.16% | 4,785,494 | – | – |
|
16
Trevi Therapeutics
TRVI
$883M
| $27.2M | 2.07% | 11,370,376 | – | – |
|
|
ALLK
17
DELISTED
Allakos
ALLK
| $26.8M | 2.05% | 6,147,260 | – | – |
|
|
DM
18
DELISTED
Desktop Metal, Inc.
DM
| $25.5M | 1.95% | 14,407,594 +8,667 | +0.1% | +$15.3K |
|
19
NextNav
NN
$2.37B
| $24.1M | 1.84% | 8,189,156 | – | – |
|
|
20
Black Diamond Therapeutics
BDTX
$157M
| $22.5M | 1.72% | 4,448,757 +1,000,000 | +29% | +$5.05M |
|
|
21
Phathom Pharmaceuticals
PHAT
$864M
| $18.3M | 1.4% | +1,276,595 | New | +$18.3M |
|
|
ZFOX
22
DELISTED
ZeroFox Holdings, Inc. Common Stock
ZFOX
| $18.1M | 1.38% | 18,068,513 | – | – |
|
|
ADAP
23
Adaptimmune Therapeutics
ADAP
$15.6M
| $15.8M | 1.21% | 17,079,778 -1 | -0% | -$1 |
|
|
INZY
24
DELISTED
Inozyme Pharma
INZY
| $13.6M | 1.04% | 2,437,689 | – | – |
|
25
Celcuity
CELC
$2.17B
| $12.7M | 0.97% | 1,250,001 | – | – |
|